Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022.
Barda N, Canetti M, Gilboa M, Indenboim V, Asraf K, Weiss-Ottolenghi Y, Amit S, Zibly D, Doolman R, Mendelson E, Harats D, Freedman LS, Kreiss Y, Lustig Y, Regev-Yochay G. Barda N, et al. Among authors: canetti m. Euro Surveill. 2022 Sep;27(39):2200701. doi: 10.2807/1560-7917.ES.2022.27.39.2200701. Euro Surveill. 2022. PMID: 36177870 Free PMC article.
Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose.
Canetti M, Barda N, Gilboa M, Indenbaum V, Asraf K, Gonen T, Weiss-Ottolenghi Y, Amit S, Doolman R, Mendelson E, Freedman LS, Kreiss Y, Lustig Y, Regev-Yochay G. Canetti M, et al. N Engl J Med. 2022 Dec 1;387(22):2092-2094. doi: 10.1056/NEJMc2211283. Epub 2022 Nov 9. N Engl J Med. 2022. PMID: 36351266 Free PMC article. No abstract available.
Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up.
Barda N, Lustig Y, Indenbaum V, Zibly D, Joseph G, Asraf K, Weiss-Ottolenghi Y, Amit S, Kliker L, Abd Elkader B, Ben-Ami E, Canetti M, Koren R, Katz-Likvornik S, Halpern O, Mendelson E, Doolman R, Harats D, Kreiss Y, Mandelboim M, Regev-Yochay G. Barda N, et al. Among authors: canetti m. Clin Microbiol Infect. 2023 Jul;29(7):918-923. doi: 10.1016/j.cmi.2023.03.007. Epub 2023 Mar 13. Clin Microbiol Infect. 2023. PMID: 36921715 Free PMC article. Clinical Trial.
Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up.
Canetti M, Barda N, Gilboa M, Indenbaum V, Mandelboim M, Gonen T, Asraf K, Weiss-Ottolenghi Y, Amit S, Doolman R, Mendelson E, Harats D, Freedman LS, Kreiss Y, Lustig Y, Regev-Yochay G. Canetti M, et al. Nat Commun. 2023 Mar 22;14(1):1593. doi: 10.1038/s41467-023-37338-7. Nat Commun. 2023. PMID: 36949080 Free PMC article. No abstract available.
Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel.
Gilboa M, Gonen T, Barda N, Cohn S, Indenbaum V, Weiss-Ottolenghi Y, Amit S, Asraf K, Joseph G, Levin T, Kanaaneh Y, Aydenzon A, Canetti M, Freedman L, Zuckerman N, Mendelson E, Doolman R, Kreiss Y, Regev-Yochay G, Lustig Y. Gilboa M, et al. Among authors: canetti m. JAMA Netw Open. 2023 May 1;6(5):e2314757. doi: 10.1001/jamanetworkopen.2023.14757. JAMA Netw Open. 2023. PMID: 37219906 Free PMC article.
Corrigendum to "Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up" [Clin Microbiol Infect] 29 (7) (2023) 918-923.
Barda N, Lustig Y, Indenbaum V, Zibly D, Joseph G, Asraf K, Weiss-Ottolenghi Y, Amit S, Kliker L, Abu-Kadar B, Ben-Ami E, Canetti M, Koren R, Katz-Likvornik S, Halpern O, Mendelson E, Doolman R, Harats D, Kreiss Y, Mandelboim M, Regev-Yochay G. Barda N, et al. Among authors: canetti m. Clin Microbiol Infect. 2024 Mar;30(3):409-413. doi: 10.1016/j.cmi.2023.12.015. Epub 2023 Dec 19. Clin Microbiol Infect. 2024. PMID: 38128780 Free PMC article. No abstract available.
36 results